Wei Gao
Manager
Boston
Education
Ph.D., biostatistics, Boston University; M.S., biostatistics, The George Washington University; B.S., mathematics, Fudan University
Summary of Experience
Dr. Gao specializes in developing innovative statistical methodologies and applying them to the study of clinical and economic outcomes in a broad range of disease areas. He has led and implemented analyses across entire product lifecycles, from early-phase clinical trials to post-market real-world evidence generation. Dr. Gao has particular expertise in retrospective data and clinical trial data analysis, health economics modeling, indirect treatment comparisons, predictive analytics, meta-analyses, individualized medicine, and statistical genetics. His research has supported the launches of several pharmaceutical products and has been widely published in leading peer-reviewed journals, including The New England Journal of Medicine, JAMA, Nature Genetics, Nature Communications, and the American Journal of Respiratory and Critical Care Medicine. He has presented his work at multiple statistical and health care conferences.
Selected Publishing
-
Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma
Clinical Genitourinary Cancer, 2020
2020Cao X, Tang D, Ratto B, Poole A, Ravichandran S, Jin L, Gao W, Swallow E, Vogelzang NJ
-
An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
Clinical Drug Investigation, 2020
2020Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Scherrer E, Wang J, Aguiar-Ibáñez R
-
Real-world healthcare resource utilization related to migraine treatment failure: a panel-based chart review in France, Germany, Italy, and Spain
Journal of Medical Economics, 2019
2019Vo P, Gao W, Zichlin ML, Fuqua E, Fadli E, Vazquez MA, Tarancón T, Mahieu N, Maier-Peuschel M, Rossi S, Naclerio M, Ritrovato D, Swallow E
-
Migraine-related healthcare resource use in the emergency department setting: a panel-based chart review in France, Germany, Italy, and Spain
Journal of Medical Economics, 2019
2019Vo P, Gao W, Zichlin ML, Fuqua E, Fadli E, Vazquez MA, Tarancón T, Mahieu N, Maier-Peuschel M, Rossi S, Naclerio M, Ritrovato D, Swallow E
-
Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Advances in Therapy, 2019
2019Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman Z, Belton L, Franklin J, Palmer S
-
Health Care Burden of Bronchopulmonary Dysplasia Among Extremely Preterm Infants
Frontiers in Pediatrics, 2019
2019Mowitz ME, Ayyagari R, Gao W, Zhao J, Mangili A, Sarda SP
-
Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
Journal of Medical Economics, 2019
2019Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Liu FX, Wang J, Aguiar-Ibáñez R
-
Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
Journal of Blood Medicine, 2019
2019Batt K, Gao W, Ayyagari R, Deschaseaux C, Vashi PB, Yao Z, Wang Y, Kessabi S, Klamroth R
News
-
October 22, 2019